BHCM
DNA icon

Brevan Howard Capital Management’s Ginkgo Bioworks DNA Stock Holding History

Brevan Howard Capital Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,401
Closed -$94.7K – 2227
2025
Q4 		$94.7K Buy
+11,401
New +$123K ﹤0.01% 1678
2025
Q2 		– Sell
-10,145
Closed -$57.8K – 1874
2025
Q1 		$57.8K Buy
+10,145
New +$103K ﹤0.01% 1085
2024
Q3 		– Sell
-13,814
Closed -$185K – 1206
2024
Q2 		$185K Buy
13,814
+5,418
+65% +$162K ﹤0.01% 906
2024
Q1 		$390K Buy
8,396
+206
+3% +$10.7K ﹤0.01% 549
2023
Q4 		$554K Buy
8,190
+5,317
+185% +$326K 0.01% 439
2023
Q3 		$208K Sell
2,873
-14,591
-84% -$1.17M ﹤0.01% 320
2023
Q2 		$1.3M Hold
17,464
– – 0.03% 77
2023
Q1 		$929K Buy
+17,464
New +$1.11M 0.02% 85

Other funds holding DNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.18B AUM 27.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return